Plain-English translation of NCT06003283 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing two different strategies for reducing doses of , a medication that helps control rheumatoid arthritis. Researchers want to find out which approach—lowering doses based on how well your disease is controlled, or spacing out doses further apart—works better at keeping your arthritis in check while potentially using less medication overall.
When arthritis medications work well, doctors want to use the lowest effective dose to reduce side effects and costs. However, it's not always clear which way of reducing this medication is safest and most effective, so this trial will help answer that question.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. One group will receive doses adjusted based on how active your arthritis is, with smaller doses given if your disease is well-controlled. The other group will receive standard doses but with longer time periods between treatments if your arthritis remains stable. You'll have regular visits to measure your disease activity and report how you're feeling, with the study continuing over an extended period to see which approach works best for you.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Belgium